COMPASS Pathways Valuation Divides Investors After Phase III Progress
A bullish valuation narrative sees a wide gap to fair value, while elevated price-to-book multiples and trial risks offer a cautionary counterpoint.
COMPASS Pathways shares closed at $12.44 on Wednesday, down 4.01% from the previous close. A Simply Wall St valuation narrative puts fair value near $24.47, while the article also highlights risks tied to trial results and funding.
The valuation is based on expectations for the company’s COMP360 program. The narrative points to completed enrollment in the COMP006 Phase III trial and a plan to use nine-week data from Part A alongside 26-week COMP005 data in a rolling regulatory application process.
The article says this approach could bring potential revenue forward and provide earlier earnings visibility. But those outcomes depend on successful Phase III results and regulatory decisions, and a funding shortfall could lead to new share issuance.
A different valuation measure points to a more cautious view. COMPASS Pathways trades at 20.4 times book value, compared with 9 times for peers and 2.1 times for the broader US biotech group, according to the article.
The contrast leaves investors weighing projected future earnings against a premium valuation. The article warns that setbacks in trials, timelines or funding could weigh on sentiment.
This article was produced with the help of AI technology.
Source: Yahoo Finance
